GARS1's core role is glycine charging of tRNA for cytosolic and mitochondrial translation. The review records the scientific judgments; the source evidence preserves original contexts, product sequences, phylogenetic assertions and source limits. The journal explains the unresolved biochemical and historical-identity questions.
Human enzyme expression and aminoacylation are directly supported by PMID:7753621(https://pubmed.ncbi.nlm.nih.gov/7753621/), PMID:7961834(https://pubmed.ncbi.nlm.nih.gov/7961834/) and PMID:7962006(https://pubmed.ncbi.nlm.nih.gov/7962006/); authentic abstracts were read. Selected original 17545306 Results and Methods establish dimer and assay scope. Its tagged-human/endogenous-mouse coimmunoprecipitation is preserved as a mixed-species context. Selected original 24898252 Methods and tRNA-contact text distinguish natural products from engineered fragments. Figure images and full supplementary construct sequences were not inspected.
The two official sequences are 739 and 685 residues, generated by alternative initiation. The short product equals precursor residues 55–739. 26327585 was read in selected original Methods, Results and captions: transcript-leader labels are not protein isoform numbers, and ER-associated translation does not mean ER-lumen localization. The predicted transit cleavage and Reactome 37–739 model coordinates are preserved as separate annotations, not silently substituted for the short-product boundary.
The current PTHR10745 tree, alignment, actual AN/PTN map and IBD lines were read and replayed. The target is AN21/PTN002473369 with an exact 739-residue sequence. The four assertions arise at AN0 or AN3, both ancestral to the target, with no intervening negative assertion. The compact evidence retains the literal donor sets, including legitimate human self-evidence. The optional family-review YAML is excluded from this gene's inputs.
19710017 directly supports ATP condensation to Ap4A. Original main Experimental Procedures/Discussion and selected supplemental Methods/captions were inspected for the distinct hydrolysis claim; no human Ap4A-to-ATP-plus-AMP assay was found there. Neither the separate phosphatase reagent nor a bacterial hydrolase discussed in the text resolves that claim. Measured synthesis remains non-core. The hydrolysis IDA is marked over-annotated because the source demonstrates a different reaction; whether human GARS1 can also hydrolyze Ap4A remains a biological question.
Selected original 17035524 Methods/Results, Figure 3 caption and Table 2 text support endogenous human neuronal and axonal localization. Images were not visually inspected. Granules are not identified as secretory granules by that staining alone. 26503042 supports extracellular release and a vesicle-enriched pool in the selected extended-data captions; the full purification Methods and images were not inspected. The Nrp1-binding mechanism applies to neuropathy mutants. Its official correction adds funding acknowledgements only.
The human secretory-granule transfer is traced to mouse 8939962. Original selected Methods/Results and GenBank U64446.1 were inspected. Current RefSeq records preserve historical linkage and the nucleotide fragment maps strongly in reverse-complement orientation to the current coding sequence, but the submitted translation does not establish the identity of the purified 23-kDa protein. The evidence is retained without asserting wrong gene, clone error or an antisense transcript. The reproducible A61 analysis includes the three official input records, offline scripts, all optimal alignments and independent literal checks. Stimulated release and the five-residue Lys-C observation are from the selected original article Methods/Results and Figure 2/3 captions; the normal publication cache contains only the abstract.
Official Reactome small-object chains resolve 380048 and 380240 through their catalysts and dimer components to UniProt P41250 in cytosol and mitochondrial matrix. These are curated models, distinct from direct localization experiments. Their source coordinates remain 37–739.
The six 32814053 human partner contexts were joined to 18 retained IntAct records, distinguishing human participants from the yeast assay host and array/pooling/validated assays. Positive pair evidence is preserved when generic protein-binding terms are removed. Clinical and large-scale proteomics bibliography entries are assessed separately; verified PubMed identity is not misrepresented as an inspected target-specific table.
The compact evidence stores all 51 literal original objects as a lossless table, their source-to-forecast joins, two complete product sequences and four IBD assertions. There are no original NOT qualifiers or extension atoms and no inherited review/journal. The genuine native fetch and untouched seed contain all 51 contexts. Actual joins agree with the private forecast and every one of the 16 export columns.
The 48-source union is complete: 16 unchanged main objects, one exact published GAN reuse and 31 missing-only acquisitions. The original 54 reference assessments are retained, with actual native title spellings reconciled. The follow-up adds one assessment of the reproducible A61 analysis, for 55 in total. All seven current excerpts match their actual repository cache bytes and portable hash/offset locators. Availability is recorded separately from the sections actually read, including earlier failed retrievals. Source bytes remain unchanged after acquisition. Target validation passed with two structured-propagation metadata advisories at native rows 24 and 48; strict GOA matching passed for all 51 original contexts, and computed status is DRAFT. Genuine CREATE history and private rendering/link checks accompany the review.
Native acquisition supplied the full PMID:28675565 text. Selected expression/aminoacylation Methods and activity/complementation Results were inspected: human WT and Arg310Gln proteins were expressed in E. coli with C-terminal His tags, and charging of transcribed human cytoplasmic tRNA-Gly was measured. This supports the existing catalytic judgment without adding a disease process or mapping engineered yeast constructs to natural products. Figure images and supplements were not inspected. The source-specific Ap4A-hydrolysis and historical granule-identity uncertainties remain unchanged.
The source-specific hydrolysis IDA now exceeds the reaction demonstrated in its cited paper and is marked over-annotated; a structured upstream check requests clarification without guessing a unique replacement. The two existing synthesis annotations remain. All 51 original contexts, both official products, the single aminoacylation core and all 48 normal source files are preserved. The reproducible A61 evidence is added separately. The shared aminoacylation process covers both cellular translation pools; no redundant parent/child process pair or generic substrate-binding annotation is added. The broad extracellular location retains released and vesicle-associated pools without assigning all extracellular material to a nonvesicular compartment. Seven current excerpts remain within their individual source budgets. Target validation passed with the two retained optional structured-propagation advisories at rows 24 and 48. Strict GOA matching passed for all 51 originals, and computed status remains DRAFT. Genuine EDIT history, private rendering and local-link/whitespace checks accompany the amendment.